We know that the needs in early development are different from the needs in late development and we tailor our approach based on information from the client and our experience with a wide range of compounds. At Crystal Pharmatech, we utilize a unique screening approach that combines the speed of automated screening with the quality of manual screening. Our scientists will provide a screen that is on scale with your early or late stage compound. The information obtained can be used to select a form, help develop or modify existing crystallization and formulation processes, or provide intellectual property.

Benefits of our solid form screening and selection services include:

1.Polymorph/Salt/Cocrystal Screening

   • Improving physical properties such as stability, hygroscopicity, and melting point
   • Increasing bioavailability for weak acids and bases or neutral compounds

2.Amorphous Solid Dispersion Screening

   • Improving the absorption of poorly soluble drugs by developing dispersion formulations
   • Identifying key risks, such as chemical and physical stability, of resulting dispersions
   • Evaluating dispersions in early and late phase formulations

3.Thermodynamic Form Relationship

   • Determining the thermodynamically stable form
   • Providing a thorough understanding of the thermodynamic relationships among the relevant solid phases of your API
   • Defining the critical controls and conditions to prevent conversion of the desired form

4.Solid Form Evaluation and Selection

   • Collecting the right information on relevant solid forms for direct comparison
   • Recommending the best solid form based on the properties of the material and your development plan
   • Providing ideas on alternative forms and formulations for long term strategic considerations

Crystal Pharmatech is the first technology-driven, China based contract research organization (CRO) that focuses on materials science and engineering for drug development. We partner with clients to ensure comprehensive solutions for their needs in solid-state research, crystallization process development, and preformulation studies. We guide clients in the discovery and selection of the optimal solid phase for drug development using all aspects of pre-formulation studies, including API process and formulation development, regulatory support and intellectual property protection.

Founded in 2010, Crystal Pharmatech has business relationships with over 60 global pharmaceutical companies. High quality service, a culture of confidentiality, and fast turnaround with cost-effective pricing are our trademarks. As we continue to grow, Crystal Pharmatech will always keep customers our number one priority. We will also continue to be at the forefront of innovation in the field of solid-state chemistry so that our customers can reap the benefits of key discoveries in an ever changing field.

Our Scientific Advisory Board includes global leaders in drug development covering amorphous dispersions, co-crystals, crystallization, solid forms, formulation and pre-formulation. The role of our board is all encompassing while we search for new scientific areas for internal and external projects.